

Supplementary Table 2. Secondary end points according to treatment group

	Total (N=91)	Raloxifene mono- therapy group (N=44)	Raloxifene/vitamin D combination therapy group (N=47)	<i>P</i> -value
Change in serum 25(OH)D level (ng/mL) from baseline to week 8	0.2±5.5	-1.5±4.7	1.8±5.8	0.0152^{a)}
Change in iPTH, level (pg/mL) from baseline to week 8	3.5±9.2	4.3±9.0	2.7±9.3	0.7549 ^{a)}
Change in iPTH, level (pg/mL) from baseline to week 16	5.9±10.6	5.9±11.6	6.0±9.6	1.0000 ^{a)}
Change in CTX level (ng/mL) from baseline to week 8	-0.1±0.1	-0.1±0.1	-0.1±0.1	1.0000 ^{a)}
Change in CTX level (ng/mL) from baseline to week 16	-0.1±0.2	-0.1±0.2	-0.1±0.1	0.3703 ^{a)}
Change in BSALP level (µg/L) from baseline to week 8	0.1±3.0	0.6±2.9	-0.3±3.0	0.2023 ^{a)}
Change in BSALP level (µg/L) from baseline to week 16	-0.7±2.9	-0.7±3.3	-0.8±2.4	1.0000 ^{a)}
Change in serum calcium level (mg/dL) from baseline to week 8	0.1±0.8	0.1±0.7	0.1±0.9	1.0000 ^{a)}
Change in serum calcium level (mg/dL) from baseline to week 16	-0.3±1.1	-0.1±0.9	-0.4±1.2	0.2994 ^{a)}
Change in serum phosphate level (mg/dL) from baseline to week 8	-0.1±0.5	-0.1±0.5	-0.1±0.5	1.0000 ^{a)}
Change in serum phosphate level (mg/dL) from baseline to week 16	-0.2±0.6	-0.1±0.6	-0.2±0.7	0.6992 ^{a)}
Drug compliance for experimental drugs	94.2±6.1	94.3±5.7	94.2±6.5	0.8921
Drug compliance for calcium carbonate	94.0±7.6	93.7±8.5	94.2±6.7	0.8147

The data is presented as mean ± standard deviation and compared using weighted 2 sample *t*-test according to the proportion of osteoporosis vs. osteopenia.

^{a)}Corrected *P*-value = *P*-value with Bonferroni's correction (level=2).

25(OH)D, 25-hydroxy-vitamin D; iPTH, intact parathyroid hormone; CTX, C-terminal telopeptide of type I collagen; BALP, bone-specific alkaline phosphatase.